Pdt Partners, LLC Atea Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.0 - $4.97 $93 - $154	-31 Reduced 0.05%	65,954 $220,000
Q4 2022 Feb 14, 2023	SELL	$4.35 - $6.17 $12,045 - $17,084	-2,769 Reduced 4.03%	65,985 $317,000
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $377,459 - $604,347	68,754 New	68,754 $391,000
Q2 2022 Aug 15, 2022	SELL	$5.33 - $8.18 $1.2 Million - $1.84 Million	-224,660 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $296,048 - $494,670	-53,827 Reduced 19.33%	224,660 $1.62 Million
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $2.14 Million - $12.4 Million	278,487 New	278,487 $2.49 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $271M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.